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Abstract
Objective The objective of this study is to report our initial
experience treating pediatric patients with central nervous
system tumors using a frameless, optically guided linear
accelerator.
Materials and methods Pediatric patients were selected for
treatment after evaluation by a multidisciplinary neuro-
oncology team including neurosurgery, neurology, pathol-
ogy, oncology, and radiation oncology. Prior to treatment,
all patients underwent treatment planning using magnetic
resonance imaging (MRI) and treatment simulation on a
standard computed tomography scanner (CT). For CT
simulation, patients were fitted with a customized plastic
face mask with a bite block attached to an optical array with
four reflective markers. After ensuring adequate reproduc-
ibility, these markers were tracked during treatment by an
infra-red camera. All treatments were delivered on a Varian
Trilogy linear accelerator. The follow-up period ranges
from 1–18 months, with a median follow-up of 6 months.
Results Nine patients, ages ranging from 12 to 19 years old
(median age 15 years old), with a variety of tumors have
been treated. Patients were treated for juvenile pilocytic
astrocytoma (JPA; n=2), pontine low-grade astrocytoma
(n=1), pituitary adenoma (n=3), metastatic medulloblasto-
ma (n=1), acoustic neuroma (n=1), and pineocytoma (n=
1). We followed patients for a median of 12 months (range
3–18 months) with no in-field failures and were able to
obtain encouraging toxicity profiles.
Conclusion Frameless stereotactic optically guided radio-
surgery and radiotherapy provides a feasible and accurate
tool to treat a number of benign and malignant tumors in




An aggressive multidisciplinary approach to the treatment
of CNS tumors frequently includes chemotherapy, radia-
tion, and surgery [1, 2]. Each of these modalities carries a
certain amount of morbidity which must be weighed against
its expected benefit. Radiation continues to play a vital role
in the curative and palliative management of intracranial
tumors in children but is frequently limited due to patient
age and associated toxicity. Children are particularly
sensitive to the potential toxicities of radiation including
cognitive impairment, skeletal growth delay/arrest, and
secondary malignancy [3].
Stereotactic radiosurgical protocols utilizing steep dose
gradients and the use of multiple intersecting conical beams
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San Diego, CA, USA[4–6] to deliver a single treatment dose with great precision
to a small treatment area have enhanced the safety by which
radiation can be delivered. Additional variants of this
technology include multi-leaf collimators (MLC),
intensity-modulated radiotherapy (IMRT) and fractionated
stereotactic radiotherapy (FSR) [4, 6, 7]. One challenge of
FSR in children, especially hyperfractionated therapy with
more than 18–25 fractions of radiation, has been to develop
a frameless system that allows for multiple treatment
sessions while maintaining treatment accuracy. In this
regard, there has been recent progress in frameless SRS
technology [8–10]. At the Moores Cancer Center of the
University of California, San Diego, children and adoles-
cents are initially fitted with a thick thermoplastic mask and
a bite block. The mask also incorporates frameless
stereotactic fiducial spheres which allows for positioning
with the accuracy of frame-based radiosurgery while
avoiding rigid head-frames. This technique allows for the
avoidance of rigid pin head fixation during therapy.
Following is our initial experience using this frameless
technique in nine pediatric patients with CNS tumors.
Materials and methods
Selected patients underwent a treatment planning MRI with
a radiosurgery protocol (fast 3D volumetric T1 scan 512×
512, 1.5 mm thickness with a 26 cm FOVand no tilt FOV).
A customized immobilization device was fabricated for
each patient consisting of a headrest, bite block, and mask.
The headrest was molded using Accuform (Med-Tec) with
the patient’s head placed in the neutral position. To develop
the bite block, a dental mold made of dental cement was
placed into the bite tray and an impression of the patient’s
upper teeth was obtained. After allowing the mold to set, an
array of four reflective markers was attached to the bite
block, placed in one plane 10–15° from the horizontal.
Using the bite block as an attachment to the patient’s teeth,
these markers are used as surrogates for patient positioning.
Patients are taken to the treatment room where the optical
guidance cameras are vaulted to the ceiling. Each patient
wears a helmet with a set of test fiducials attached. The
patient inserts and removes the bite block (with the markers
attached) ten times and each time the relative positioning
error is measured. Variation in positioning of <0.75 mm, as
measured by the optical guidance camera, was considered
acceptable. Once reproducibility has been assessed, patients
were taken to the CT simulator. Here, the thermoplastic
mask was placed over the patient’s head and molded to
their face. With the mask and bite block in place, the
patients underwent simulation CT (FOV 35 cm, 1.25 mm
slice thickness, with no contrast), with minimization of
metal artifact (Fig. 1).
Following CT registration, the FastPlan software detects,
registers, and verifies the fiducial markers (Fig. 2). The CT
and planning MR images were then fused (both manually
and automatically) using a rigid auto-registration tool with
mutual information metrics (Fig. 3). Varian’s Eclipse
treatment planning system was used and target volume
and normal organ-at-risk (OAR) volumes were then
contoured by the treating radiation oncologist and neuro-
surgeon. Margins were added at the discretion of the
treating radiation oncologist, and were typically 1–3 mm.
No margin was added to any contoured OAR. After
meticulous target volume contouring, treatment planning
commenced. Isocenter placement was either automatic or
manual. The two collimators utilized at the UCSD Moores
Cancer Center are the conical collimator on arc and the
Fig. 1 Patient undergoing a CT
(FOV 35 cm, 1.25 mm slice
thickness, no contrast) with
mask and bite block in place
838 Childs Nerv Syst (2009) 25:837–844MLC with IMRs (Table 1). Standard arcs were selected
from a database and the treatment dose and isodose lines
were then delineated. Each fiducial on the bite block was
digitized, with an average error in fiducial position of less
than 0.75 mm. The appropriate collimator (intensity-
modulated radiosurgery with multi-leaf collimation or
cone-based stereotactic radiosurgery) was attached and
verified via the Winston–Lutz test, used for mechanical
accuracy of the isocenter. Final adjustments were made
using the optical array.
Throughout treatment, patients were observed via audio
and visual monitors. Maintenance of patient positioning
was assessed by the optical guidance camera. Our protocol
is to interrupt treatment if there is a greater than 0.75 mm
displacement of the reflective markers. This did not occur
in this series, and all treatments were uninterrupted.
Following completion of treatment, the mask, bite block,
and array were removed. There were no specific treatment-
related restrictions following completion of therapy.
Treatments/results
Out of an initial ten patients, nine were able to tolerate the
procedure without requiring general anesthesia. Median age
was 15 years (range=12–19 years). Two patients presented
with juvenile pilocytic astrocytoma (JPA), one patient with
a left pontine low-grade astrocytoma, three patients with
pituitary adenoma, one patient with metastatic medullo-
blastoma, one patient with bilateral acoustic schwannomas,
and one patient with a pineocytoma (who had previously
undergone optically guided frameless SRS and SRT;
Table 1).
In all cases, the treatment was well tolerated with no
acute toxicity requiring intervention. With a median follow-
up of 12 months (range 3–18 months), no significant
delayed toxicities have been observed. The radiographic
imaging for Patients 1, 2, 5 and 7 are presented in Fig. 4–6.
Fig. 3 The CT and MRI are manually fused, and then auto-fused
Fig. 2 With the CT registration, the Fastplan software detects,
registers, and verifies fiducial markers
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In the pediatric population, there are typically significant
concerns regarding treatment-related radiotoxicity, includ-
ing potential neurocognitive and neuropsychological defi-
cits, endocrine abnormalities, cerebral atrophy, skeletal
bone growth delay/arrest, and secondary malignancy [11,
12]. Toxicity is known to be associated with the volume as
well as nature of irradiated tissue. For example, reducing
the amount of radiation exposure to normal brain paren-
chyma helps to minimize adverse treatment effects. Focal
radiosurgery appears to have a better safety profile in
preventing children’s cognitive decline than whole-brain
radiotherapy [12–17]. For such reasons, stereotactic radio-
therapy is becoming a more integral part of brain tumor
treatment in children.
Radiosurgery is able to deliver a high dose of radiation
to a small target volume while providing relative sparing of
surrounding normal tissue. The pediatric population
presents unique difficulties in that general anesthesia and
endotracheal intubation are often required to ensure
compliance with head immobilization [18–20]. Other
potential hazards related to head fixation include the risk
of skull fracture with possible associated intracranial
hemorrhage, especially in pediatric patients with thinner
skulls and potential osteopenia secondary to past radiation
treatments [12, 19]. As a result, fractionated and hyper-
fractionated therapy with upward of 18–25 treatments can
Table 1 Patients, their diagnoses and treatment plans





1 Low-grade astrocytoma 16Y 28×1.8 Gy IMRS with MLC Yes 12 Resolution
2 Juvenile Pilocytic
Astrocytoma
12Y 1×20 Gy Conical Collimators Yes 6 Resolution
3 Pituitary Macroadenoma 15Y 28×1.8 Gy IMRS with MLC Yes 12 Required another resection
4 Acoustic Schwannoma 16Y 28×1.8 Gy IMRS with MLC No 3 Stable
5 Medulloblastoma Metastasis 12Y 14×1 Gy Conical Collimators Yes 12 Stable
6 Pituitary Prolactinoma 18Y 28×1.8 Gy IMRS with MLC Yes 18 Stable
7 Pineocytoma 19Y 5×5 Gy IMRS with MLC No 12 Local control with subsequent metastasis
8 Juvenile Pilocytic
Astrocytoma
14Y 1×20 Gy Conical Collimators No 10 Stable
9 Pituitary Macroadenoma 12Y 28×1.8 Gy IMRS with MLC Yes 15 Decreased GH level
Patient number 3: a 15-year-old female with a growth-hormone-secreting pituitary macroadenoma, underwent subtotal resection in December of
2005. Post-operatively had residual tumor in the right cavernous sinus that encased the cavernous portion of the carotid artery as well as the
proximal right middle cerebral artery and anterior communicating artery. On serial MRI, she was noted to have subsequent tumor growth and
marked mass effect on the optic chiasm. In August of 2006, she underwent fractionated radiotherapy to a dose of 50.4 Gy in 28 fractions of
1.8 Gy. She tolerated the procedure well but on follow-up MRI, there was growth of her residual tumor, and she underwent a second resection in
November of 2006
Patient number 4: a 16-year-old male with a history of type II neurofibromatosis with bilateral acoustic and trigeminal nerve neuromas. He
received a course of fractionated IMRT to his left acoustic neuroma, which measured 2.5 cm in maximal diameter. He received a dose of 50.4 Gy
in 28 fractions of 1.8 Gy. Post-therapy, he was able to maintain hearing bilaterally without any new neurological deficits. There was no change in
the size of his neuroma but there was some hypointensity in the central portion of the lesion suggestive of radiation therapy effect
Patient number 6: an 18-year-old male with a history of recurrent pituitary prolactinoma following multiple resections, most recently on December
of 2005. Residual disease was noted involving the left cavernous sinus and associated left internal carotid artery. The patient continued to have
elevated levels of prolactin despite aggressive endocrinologic intervention and his MRI was concerning for recurrence. He received a course of
external beam stereotactic radiotherapy to his pituitary region to a dose of 50.4 Gy, completed in April 2006. He tolerated the procedure and his
existing bitemporal hemianopsia remains stable. He had no other neurological deficits. Follow-up MRI in November of 2006 indicated no increase
in size of the pituitary mass with mild interval decrease in enhancement of the solid component, likely related to necrosis
Patient number 8: a 14-year-old male, post-two-surgical resections for a posterior fossa JPA with 1 cm residual adjacent to the site of the tumor
resection. He underwent SRS to a dose of 20 Gy. The patient tolerated the procedure well. At 10 months post-treatment, a follow-up MRI
demonstrated regression of the lesion
Patient number 9: a 12-year-old male with a pituitary adenoma and acromegaly who underwent a resection in October of 2005. The patient had a
residual intracavernous lesion measuring 1.4 cm×1.0 cm and received a dose of 50.4 Gy in May of 2006 with no complications. He has been
continued on methimazole and somatostatin with reduction in his growth hormone levels. He suffered no focal neurological deficits and tolerated
the procedure well
840 Childs Nerv Syst (2009) 25:837–844be challenging in this population. GammaKnife® has
remained the gold standard for radiosurgical treatment for
many years. GammaKnife® Radiosurgery (GKR) intro-
duced by Lars Leksell in 1958 allows for accurate and
focused targeting via the use of up to 201 individual
radiation sources [21]. Treatment limitations in children are
related to the duration of therapy, the use of rigid head
fixation, and limitation to intracranial targets [12–17, 22,
23]. There has been a plethora of data utilizing GKR in
children though a majority of the published experience
details the treatment of arteriovenous malformations (AVM)
[13, 14, 24–27].
Advancements in motion management have allowed for
the development of frameless techniques [12, 28, 29]. In
adults, the use of frameless techniques has not been
associated with any detriment to tumor control [10, 30–
Fig. 4 a Patient 1 was a 16-year-old male with biopsy diagnosed left
pontine low-grade astrocytoma (A1) underwent external beam radio-
therapy to a dose of 5,400 cGy without complication (A2). He
subsequently finished a course of Temodar in August of 2007. Prior to
therapy, he was drooling and had a gait disturbance that has since
resolved. He suffered from left-sided hearing loss, which has been
stable since treatment and diplopia, corrected by glasses. b Patient 2
was a 12-year-old male diagnosed with juvenile pilocytic astrocytoma
resected in 2001 and several years of chemotherapy (vincristine and
carboplatin) completed in 2003. Follow-up imaging demonstrated a
recurrence with a 10×12 mm nodule along the anterior inferior fourth
ventricle (B1). He underwent SRS in April of 2007. He tolerated the
procedure well. Subsequent MRI demonstrated complete response,
with slight residual enhancement in the surgical bed, with no nodular-
appearing enhancement (B2). c Patient 5 was a 12-year-old male
diagnosed with medulloblastoma in 2003, underwent a gross-total
resection with adjuvant chemotherapy and craniospinal radiotherapy.
He received 36 Gy of craniospinal radiation with a posterior fossa
boost in October of 2003 along with vincristine, completed in October
of 2004. In June 2004, he was found to have recurrent cerebellar
enhancement and diffuse leptomeningeal spread, and he was treated
with temozolomide, etoposide, and cyclophosphamide. In 2006, MRI
revealed an area of enhancement in the right frontoparietal region
(C1), and he received radiosurgery with 14 Gy, which the patient
tolerated well. He now has local control at the frontoparietal site but
continues to have leptomeningeal disease (C2)
Childs Nerv Syst (2009) 25:837–844 84132]. Recently, several linear accelerator-based radiosurgical
techniques have emerged including Cyberknife® (Accuray-
Sunnyvale, CA), Trilogy (Varian Medical Systems- Palo
Alto, CA), and Novalis (BrainLab AG) linear accelerator
(LINAC) treatment systems [4, 33–37]. The Cyberknife® is
a 6 MV LINAC mounted on a robotic arm, allowing for
radiotherapy with the precision necessary to treat intracra-
nial and extracranial tumors independent of frame-based
rigid immobilization. Several series have been published
detailing clinical experience in treating pediatric patients
with this system [12, 38]. Although Cyberknife® allows
treatment of extracranial tumors and facilitates fractionated
radiotherapy in the pediatric population, each treatment
session generally lasts 60–90 min [39–41]. Large complex
lesions may require treatment plans with multiple isocenters
and increased treatment times which could require in-
creased use of sedation in the pediatric population.
Additionally, as opposed to the continuous monitoring of
the optical guidance system described in this report,
intrafraction motion management with Cyberknife is ac-
complished using periodic X-ray images which results in
additional patient exposure to non-therapeutic ionizing
radiation [12, 38]. Cyberknife® also does not allow for
intensity modulation.
Trilogy and Novalis are LINAC systems that allow
frameless targeting and single-fraction or fractionated
treatment of intra- and extracranial lesions [4, 6, 36]. In
addition to conical collimators, both Trilogy and Novalis
utilize a multi-leaf collimator (MLC) with radiation
treatment adapted to the shape of complex tumors,
facilitating treatment and precluding the need for multiple
isocenters. Other advantages include the use of intensity
modulation to help limit toxicity to surrounding tissue [7]
and treatments delivered in less than 30 min limiting the
need for sedation. The frameless software used at UCSD
allows for continuous patient monitoring utilizing infra-red
optical guidance to track the patients’ position during
treatment delivery. Trilogy is novel in its use of optical
guidance (non-ionizing radiation) for accuracy, sparing the
patient additional radiation exposure.
Fig. 5 Patient 7 was a 19-year-
old female diagnosed with a
large (4.8 cm×4.0 cm×4.4 cm)
cystic lesion in her pineal region
in July 2006. She underwent a
subtotal resection revealing
pineocytoma with increased
mitotic activity. On her post-
operative scan, a 15×16-mm
enhancing nodule in the trigone
of her left lateral ventricle and
an 8×6-mm enhancing nodule
in the floor of the third ventricle
were discovered. She underwent
a second surgical resection but
continues to have residual tumor
on post-operative MRI (a, b).
She received a fractionated
course of radiosurgery to a dose
of 2,500 cGy over five fractions,
November 2006. She tolerated
the procedure well and her pre-
treatment gait disturbance im-
proved dramatically and on MRI
of January 2007 (c, d)
842 Childs Nerv Syst (2009) 25:837–844Conclusion
In this retrospective study, we present our initial experience
with pediatric and adolescent patients who underwent SRS
and FSR with frameless optical guidance using the Trilogy
linear accelerator system. There are several advantages to
this system including the frameless technique, short beam-
on times, and continuous motion monitoring without the
need for additional ionizing radiation exposure. No patients
suffered treatment-related toxicities or developed new
neurological deficits in follow-up and most patients either
achieved stabilization or resolution of their tumors.
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